Dr Lal PathLabs Q2 Results: Revenue Touches ₹874 Crore, Net Profit Rises 27.5%; Dividend Of ₹5 Declared

Dr Lal PathLabs recorded year-on-year growth in both revenue and net profit during the September quarter of FY27. Revenue reached ₹874 crore, marking a 19.6% increase. Net profit advanced at a faster rate, rising 27.5% to ₹194 crore.

The company also reported a 25.1% rise in EBITDA. Operating margins moved higher during the quarter. Across the first half of FY27, revenue growth remained near the 20% mark.

The financial results were announced on 4 November 2026, after the board convened. The meeting also covered the interim dividend for the current financial year. The declared amount was ₹5 per share.

Dr Lal PathLabs Q2 FY27 Results: Key Financial Highlights

The company's consolidated financial performance for the quarter ended 30 September 2026 showed broad-based growth across major profitability measures.

Dr Lal PathLabs Share Price: Stock Gains 6.2%

Dr Lal PathLabs shares closed at ₹2,029.40 on the National Stock Exchange (NSE) on 4 November, gaining ₹103.70 over the previous close of ₹1,925.70. The stock touched an intraday high of ₹2,049, also marking its fresh 52-week high.

First-Half Performance And Dividend Announcement

For the six months ended September 2026, the company maintained its growth momentum.

Revenue increased 19.4% to ₹1,672 crore.

• EBITDA rose 26.7% to ₹528 crore.

• EBITDA margin improved to 31.6%.

• Net profit climbed 27.3% to ₹364 crore.

The company announced an interim dividend of ₹5 per equity share, equivalent to 50% of the face value. Its cash and cash equivalents stood at ₹1,746 crore as at 30 September 2026.

Diagnostic Network And Business Operations

Dr Lal PathLabs operates an integrated diagnostic services network catering to individual patients, hospitals, healthcare providers and corporate customers.

As disclosed in its investor release, the company had 312 clinical laboratories, 7,727 Patient Service Centres and 13,935 pick-up points as at 31 March 2026. Its network includes reference laboratories in Delhi, Kolkata, Bengaluru and Mumbai.

The September-quarter results underline the company's continued revenue expansion and improvement in operating profitability, with first-half earnings growth also remaining ahead of revenue growth.

Source

NSE

Also Read - Closing Bell, 4 November 2026: Benchmarks Remain Range-Bound Through Most Of The Session; Close In The Positive